Contribute Try STAT+ Today

Hello, everyone, and how are you this morning? We are doing just fine, thank you, now that the short person has left for the summer job and our official mascots have quietly settled into their official snoozing positions. As for us, no snoozing is allowed. There is much to be done. So please join us as we fire up the coffee kettle for another cup of stimulation — southern pecan is the choice of the day, for those who track such things. Meanwhile, here are some items of interest to help you on your journey. Hope all goes well and, as always, please do keep in touch …

AstraZeneca (AZN) is the latest drug maker to freeze prices in the U.S. for the rest of 2018, Reuters writes. The move comes as the Trump administration tries to complete a blueprint for lowering drug costs and, in particular, follows criticism from President Trump as he struggles to follow through on an oft-stated commitment to solve the problem. In recent weeks, Pfizer (PFE), Novartis (NVS) and Roche (RHHBY) agreed to either defer or freeze price cuts through the rest of the year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.